| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9101435 | Seminars in Arthritis and Rheumatism | 2005 | 4 Pages |
Abstract
Registration of new chemical entities to be used in the management of GIOP should be granted, based on a 1-year noninferiority trial, using BMD as primary outcome and alendronate or risedronate as comparator. Demonstration of antifracture efficacy should have been previously demonstrated in PMO.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Eric C. MD, Jean-Pierre MD, PhD, Johann D. MD, Dominique J. MD, Gilles M. MD, Gottfried MD, Andrea MD, John J. MD, Philippe M. MD, PhD, Pierre D. MD, PhD, Willard H. MD, PhD, Jaime MD, PhD, Roy D. MD, Bernard P. MD, Charles J. MD, Luc MD, PhD,